Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

摘要: Objective: •To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated sunitinib. Patients and Methods: •We reviewed charts mRCC who started sunitinib as a first targeted treatment between 2005 2012 three hospitals Belgium France. •Collected data included known prognostic factors for mRCC, anatomical location sites, response rate (RR), progression-free survival (PFS) overall (OS). Results: •A total 200 eligible were identified by retrospective chart review. The median PFS OS 12 20 months, respectively. •We observed clear CRP levels outcome: was 25 months group ≤5 mg/L 8 >5 mg/L (hazard ratio [HR] 2.48, 95% CI 1.74–3.59). each 50 vs respectively (HR 3.17, 2.20–4.68). In ≤5 mg/L, 61% experienced partial compared 32% (difference = 29%, 15–42). •When adding (with log transformation) to six variables International Metastatic RCC Database Consortium (IMDC) model multivariable Cox regression model, independently associated poor doubling level: 1.14, 1.03–1.26; P 0.01) (HR: 1.29, 1.16–1.43; < 0.001). •Adding increased c-statistic at 5 years from 0.63 (0.59–0.68) 0.69 (0.65–0.73), 0.65 (0.60–0.69) 0.70 (0.66–0.74). •Patients elevated had prognosis independent IMDC risk group, whereas low favourable very good outcome. Conclusion: •Baseline is strong variable linked RR, sunitinib.